REGN FY 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14.3B+1.0% YoY

Gross Profit

$12.2B85.4% margin

Operating Income

$3.6B24.9% margin

Net Income

$4.5B31.4% margin

EPS (Diluted)

$41.48

Cash Flow

Operating Cash Flow

$5.0B

Free Cash Flow

$4.1B

Stock-Based Comp.

$994M

Balance Sheet

Total Assets

$40.6B

Total Liabilities

$9.3B

Stockholders' Equity

$31.3B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14.3B	$14.2B	+1.0%
Gross Profit	$12.2B	$12.2B	+0.1%
Operating Income	$3.6B	$4.0B	-10.3%
Net Income	$4.5B	$4.4B	+2.1%